Kezar Life Sciences (KZR) Q4 2024 & Study Result earnings summary

Executive summary

• PORTOLA Phase 2a trial evaluated zetomipzomib in relapsed or refractory autoimmune hepatitis (AIH), enrolling 24 patients, most on background steroid therapy, and demonstrated rapid, durable, and steroid-sparing biochemical remission versus placebo in a difficult-to-treat population.

• 36% of zetomipzomib-treated patients on steroid-based therapy achieved steroid-sparing complete biochemical remission (CR) by Week 24 versus 0% in placebo; in the ITT population, 31.3% achieved CR versus 12.5% for placebo.

• No disease flares occurred in zetomipzomib CR patients, with histologic and elastography improvements observed after 6 months.

• The safety profile was favorable, with most adverse events mild to moderate, no increased infection risk, and no deaths or opportunistic infections.

• The trial is the first randomized study to show successful outcomes in this difficult-to-treat AIH population, supporting advancement to registrational development.

Financial highlights

• No direct financial results were disclosed for the trial, but positive clinical data positions zetomipzomib as a potential first-in-class therapy, supporting future investment and development.

• Cash, cash equivalents, and marketable securities totaled $132.2 million as of December 31, 2024, down from $201.4 million at year-end 2023, mainly due to operational spending.

• Revenue decreased by $7.0 million in 2024 compared to 2023, reflecting the prior year’s upfront payment from Everest Medicines.

• R&D expenses for 2024 decreased by $20.0 million to $65.7 million, driven by strategic restructuring and lower personnel and early-stage research costs.

• Net loss for 2024 was $83.7 million ($11.49 per share), an improvement from $101.9 million ($14.04 per share) in 2023.

Outlook and guidance

• Next steps include responding to the FDA regarding a partial clinical hold and planning for a potential registrational study in collaboration with FDA and EMA.

• Biochemical remission with steroid taper and histologic improvement expected to be key endpoints in pivotal studies.

• Full data, including matured open-label extension (OLE) results, will be presented later in the year, with a major conference presentation planned for the second half of 2025.

• Forward-looking statements highlight potential for zetomipzomib in multiple autoimmune diseases and ongoing clinical development.